GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bridge Biotherapeutics Inc (XKRX:288330) » Definitions » EV-to-EBITDA

Bridge Biotherapeutics (XKRX:288330) EV-to-EBITDA : -1.35 (As of Jun. 03, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Bridge Biotherapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bridge Biotherapeutics's enterprise value is ₩46,986.6 Mil. Bridge Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-34,763.5 Mil. Therefore, Bridge Biotherapeutics's EV-to-EBITDA for today is -1.35.

The historical rank and industry rank for Bridge Biotherapeutics's EV-to-EBITDA or its related term are showing as below:

XKRX:288330' s EV-to-EBITDA Range Over the Past 10 Years
Min: -221.54   Med: -3.67   Max: 67.17
Current: -1.35

During the past 8 years, the highest EV-to-EBITDA of Bridge Biotherapeutics was 67.17. The lowest was -221.54. And the median was -3.67.

XKRX:288330's EV-to-EBITDA is ranked worse than
100% of 452 companies
in the Biotechnology industry
Industry Median: 9.47 vs XKRX:288330: -1.35

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-03), Bridge Biotherapeutics's stock price is ₩2315.00. Bridge Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-1726.000. Therefore, Bridge Biotherapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Bridge Biotherapeutics EV-to-EBITDA Historical Data

The historical data trend for Bridge Biotherapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bridge Biotherapeutics EV-to-EBITDA Chart

Bridge Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial 27.67 -11.74 -9.15 -4.56 -1.47

Bridge Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.28 -2.16 -2.03 -1.47 -3.41

Competitive Comparison of Bridge Biotherapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Bridge Biotherapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bridge Biotherapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bridge Biotherapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bridge Biotherapeutics's EV-to-EBITDA falls into.



Bridge Biotherapeutics EV-to-EBITDA Calculation

Bridge Biotherapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=46986.620/-34763.514
=-1.35

Bridge Biotherapeutics's current Enterprise Value is ₩46,986.6 Mil.
Bridge Biotherapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-34,763.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bridge Biotherapeutics  (XKRX:288330) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Bridge Biotherapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2315.00/-1726.000
=At Loss

Bridge Biotherapeutics's share price for today is ₩2315.00.
Bridge Biotherapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-1726.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Bridge Biotherapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bridge Biotherapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bridge Biotherapeutics (XKRX:288330) Business Description

Traded in Other Exchanges
N/A
Address
58, Pangyo - ro, Gyeonggi No. 303, 255 beongil Seas Tower in Bundang Pangyo, Seongnam-si, KOR, 13486
Bridge Biotherapeutics Inc is a drug research and development company. It operates in the pharmaceutical and bio industry. The company has two pipeline clinical-stage products namely, BBT-401 and BBT-877.

Bridge Biotherapeutics (XKRX:288330) Headlines

No Headlines